Enables several functions, including G-protein alpha-subunit binding activity; corticotropin-releasing hormone binding activity; and corticotropin-releasing hormone receptor activity. Involved in several processes, including G protein-coupled receptor signaling pathway; learning or memory; and regulation of secretion by cell. Located in several cellular components, including multivesicular body; neuronal cell body; and trans-Golgi network. Used to study hypertension. Biomarker of several diseases, including depressive disorder; functional colonic disease; irritable bowel syndrome; thromboangiitis obliterans; and type 2 diabetes mellitus. Human ortholog(s) of this gene implicated in asthma; chronic obstructive pulmonary disease; and obesity. Orthologous to several human genes including CRHR1 (corticotropin releasing hormone receptor 1); PARTICIPATES IN corticotropin-releasing hormone signaling pathway; G protein mediated signaling pathway via Galphas family; long term depression; INTERACTS WITH (R)-noradrenaline; 2,4,6-trinitrobenzenesulfonic acid; ammonium chloride.
[CP 154526 binds to and results in decreased activity of CRHR1 protein] inhibits the reaction [Morphine deficiency affects the abundance of Norepinephrine] and [CP 154526 binds to and results in decreased activity of CRHR1 protein] inhibits the reaction [Naloxone affects the abundance of Norepinephrine]
[Tetrachlorodibenzodioxin co-treated with 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide] results in decreased expression of CRHR1 mRNA
[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP and Progesterone promotes the reaction [[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP]
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3 more ...
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3 more ...
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3 more ...
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3 more ...
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3 more ...
Pentobarbital inhibits the reaction [Corticotropin-Releasing Hormone results in decreased activity of CRHR1 protein] and Pentobarbital inhibits the reaction [Corticotropin-Releasing Hormone results in increased expression of CRHR1 mRNA]
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3 more ...
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3 more ...
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3 more ...
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3 more ...
[CP 154526 binds to and results in decreased activity of CRHR1 protein] inhibits the reaction [Morphine deficiency affects the abundance of Norepinephrine] more ...
[CP 154526 binds to and results in decreased activity of CRHR1 protein] inhibits the reaction [Naloxone affects the abundance of Norepinephrine] more ...
Pentobarbital inhibits the reaction [Corticotropin-Releasing Hormone results in decreased activity of CRHR1 protein] and Pentobarbital inhibits the reaction [Corticotropin-Releasing Hormone results in increased expression of CRHR1 mRNA]
perfluorooctane sulfonic acid results in decreased expression of CRHR1 mRNA and perfluorooctane sulfonic acid results in decreased expression of CRHR1 protein
Progesterone promotes the reaction [[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP] and Progesterone promotes the reaction [CRHR1 protein binds to and results in increased activity of CRH protein]
Sex differences in corticotropin-releasing factor receptor signaling and trafficking: potential role in female vulnerability to stress-related psychopathology.
Augmented Cocaine Seeking in Response to Stress or CRF Delivered into the Ventral Tegmental Area Following Long-Access Self-Administration Is Mediated by CRF Receptor Type 1 But Not CRF Receptor Type 2.
Corticotropin-releasing hormone (CRH) downregulates the function of its receptor (CRF1) and induces CRF1 expression in hippocampal and cortical regions of the immature rat brain.
Genetic variation in the corticotrophin-releasing factor receptors: identification of single-nucleotide polymorphisms and association studies with obesity in UK Caucasians.
Gestational hypoxia alone or combined with restraint sensitizes the hypothalamic-pituitary-adrenal axis and induces anxiety-like behavior in adult male rat offspring.
Enduring, handling-evoked enhancement of hippocampal memory function and glucocorticoid receptor expression involves activation of the corticotropin-releasing factor type 1 receptor.
The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology.
Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
Interactive effects of prenatal alcohol exposure and chronic stress in adulthood on anxiety-like behavior and central stress-related receptor mRNA expression: Sex- and time-dependent effects.
Alterations in colonic corticotropin-releasing factor receptors in the maternally separated rat model of irritable bowel syndrome: differential effects of acute psychological and physical stressors.
Urocortin, but not urocortin II, protects cultured hippocampal neurons from oxidative and excitotoxic cell death via corticotropin-releasing hormone receptor type I.
The pseudo signal peptide of the corticotropin-releasing factor receptor type 2a decreases receptor expression and prevents Gi-mediated inhibition of adenylyl cyclase activity.
Corticotropin-releasing factor receptor types 1 and 2 are differentially expressed in pre- and post-synaptic elements in the post-natal developing rat cerebellum.
Reduced hypothalamic POMC and anterior pituitary CRF1 receptor mRNA levels after acute, but not chronic, daily "binge" intragastric alcohol administration.
Alterations in hypothalamic-pituitary-adrenal axis activity and in levels of proopiomelanocortin and corticotropin-releasing hormone-receptor 1 mRNAs in the pituitary and hypothalamus of the rat during chronic 'binge' cocaine and withdrawal.
mediates hippocampal neuron protection from oxidative and exitotoxic stress-induced injury through signaling pathways that involve protein kinase C, cAMP-dependent protein kinase, and mitogen-activated protein kinase